Investors in Grail, Inc. (NASDAQ: GRAL) have until August 4, 2026, to seek appointment as lead plaintiff in a securities class action lawsuit concerning alleged violations of federal securities laws. The litigation follows a significant stock decline after the company disclosed that its NHS-Galleri cancer screening trial failed to meet its primary endpoint. Hagens Berman Sobol Shapiro LLP and The Rosen Law Firm are actively urging investors with substantial losses to submit their claims and secure counsel before the deadline. The case is pending in the U.S. District Court for the Northern District of California, and the deadline applies to those who purchased Grail common stock between May 13, 2025, and February 19, 2026.

Allegations Regarding NHS-Galleri Trial

The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Grail, a commercial-stage healthcare company, developed the Galleri test to screen for multiple cancers via blood samples. The NHS-Galleri trial aimed to demonstrate a statistically significant reduction in late-stage (Stage III and IV) cancers. The lawsuit alleges that Grail made positive statements about the trial design and top-line results, claiming it was designed with three consecutive years of screening to achieve the primary endpoint. However, the complaint contends the three-year timeframe was actually insufficient to demonstrate the endpoint, and the company misrepresented the trial's progress.

Hagens Berman partner Reed Kathrein stated the firm’s investigation focuses on when Grail and its management first recognized that the required follow-up period diverged from the touted three-year duration. The action centers on whether Grail selectively promoted favorable top-line results from initial screening rounds while withholding granular data and ignoring internal indicators suggesting that a three-year timeline would be insufficient to achieve the trial’s primary endpoint.

Market Impact and Financial Fallout

On February 19, 2026, Grail announced top-line results revealing the trial did not meet its primary endpoint. The company stated that a statistically significant Stage III-IV reduction was not observed and attributed the outcome partly to probably needing a longer follow-up time. This disclosure caused Grail's stock price to decline $51.32 per share, or 50.55%, the following day, erasing over $2.2 billion in market capitalization.

Legal Proceedings and Investor Rights

Under the Private Securities Litigation Reform Act of 1995, the court appoints a lead plaintiff to represent the interests of all class members. The lead plaintiff selects counsel, oversees litigation strategy, and ensures the case is prosecuted in the best interest of the class. In the Grail action, the lead plaintiff will represent shareholders who purchased GRAL stock during the Class Period at prices that were allegedly artificially inflated by misleading statements about the NHS-Galleri trial's prospects. Any investor who purchased GRAL securities during the Class Period may apply to serve as lead plaintiff, and the court generally appoints the applicant with the largest financial interest in the relief sought. Lead plaintiffs are not required to pay any fees or costs; securities class actions are prosecuted on a contingency basis.

The Rosen Law Firm, represented by Laurence Rosen and Phillip Kim, has also issued a notice reminding investors of the August 4 deadline. The firm encourages investors to select qualified counsel with a track record of success in leadership roles, noting that some firms issuing notices may act merely as middlemen. Investors can join the class action by visiting rosenlegal.com/cases/grail-inc/join or calling 866-767-3653.

Investors who do not seek lead plaintiff appointment by August 4, 2026, are not excluded from the case. Absent class members retain the right to participate in any settlement or judgment without taking any action at this time. The deadline applies solely to those who wish to serve in the lead plaintiff role. After the deadline, the court will review all motions and appoint the lead plaintiff. Once appointed, the lead plaintiff and its chosen counsel will file a consolidated amended complaint, and the litigation proceeds through discovery and potential resolution. This process typically spans two to four years.

GRAIL, Inc. has entered a collaboration with Priority Health to make GRAIL's Galleri multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. This partnership aims to enhance cancer screening coverage by integrating the Galleri test into existing plans. Priority Health, a nationally recognized nonprofit health plan serving more than 1.4 million members, is the third largest provider-sponsored health plan in the nation.

Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025. The latest expansion makes Priority Health the first Michigan health plan to enable its employer groups to easily add the Galleri test to their cancer screening coverage. The collaboration allows employers to integrate the test into customized benefit programs that include Priority Health's extensive provider network and care management services.

Key Details of the Collaboration

The Galleri test is designed to detect multiple types of cancer early, potentially improving treatment outcomes. With a simple blood draw, Galleri screens for many of the deadliest cancers before symptoms appear. When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up. The test is supported by rigorous studies in intended use populations and is the only available MCED test with demonstrated performance in patients being screened for cancer.

"Early cancer detection can lower health care costs by enabling less intensive, more effective treatments," said Megan Hall, PhD, vice president of Medical Affairs at GRAIL. "Priority Health is leading the way in innovative employee benefit offerings, and we are excited to collaborate to bring Galleri to their customers while expanding broader market access."

"At Priority Health, we care about helping employers create benefits that truly work for their teams," said Chase Osbourne, senior vice president of employer solutions & innovation at Priority Health. "By partnering with GRAIL, we're making it easier for employers to support early cancer detection and proactive health."